ТЕСТИРОВАНИЕ ФУНКЦИИ ТРОМБОЦИТОВ ДЛЯ ОЦЕНКИ РИСКА ТРОМБОЗОВ И КРОВОТЕЧЕНИЙ У БОЛЬНЫХ ИБС, ПОЛУЧАЮЩИХ АНТИАГРЕГАНТЫ
https://doi.org/10.15829/1560-4071-2015-3-25-34
Аннотация
Обзор посвящён тестированию функции тромбоцитов у больных ИБС, получающих антиагрегантные препараты. Приведены результаты основных крупных исследований, продемонстрировавших связь уровня остаточной реактивности тромбоцитов с развитием ишемических и геморрагических осложнений. Проведен анализ возможных причин недостаточного подавления функции тромбоцитов в ответ на прием клопидогрела. Рассмотрены предложения международных экспертных организаций по оценке чувствительности к антиагрегантам и возможной модификации антитромбоцитарного лечения.
Об авторах
А. Л. Комаров
ФГБУ Российский кардиологический научно-производственный комплекс Министерства здравоохранения РФ, Москва, Россия.
Россия
Россия
д.м.н., в.н.с. лаборатория клинических проблем атеротромбоза
Е. П. Панченко
ФГБУ Российский кардиологический научно-производственный комплекс Министерства здравоохранения РФ, Москва, Россия.
Россия
Россия
профессор, д. м.н., руководитель лаборатории клинических проблем атеротромбоза
Список литературы
1. Diagnosis and treatment of patients with acute myocardial infarction with st-segment elevation ECg. VnOK guidelines. Cardiovascular therapy and Prevention, 2007;6 (8), suppl. 1. Russian (Диагностика и лечение больных острым инфарктом миокарда с подъемом сегмента st экг. Рекомендации ВНОК. кардиоваскулярная терапия и профилактика 2007;6 (8), Приложение 1).
2. National guidelines for the treatment of ACS without persistent st elevation on ECg. VNOK guidelines. Cardiovascular therapy and Prevention, 2006; 5(8), suppl. 1. Russian (Национальные рекомендации по лечению Окс без стойкого подъема st на экг Рекомендации ВНОк. кардиоваскулярная терапия и профилактика 2006; 5(8), Приложение 1).
3. National recommendations for antithrombotic therapy in patients with stable manifestations of atherothrombosis. VNOK guidelines. Cardiovascular therapy and Prevention, 2009; 8(6), suppl. 6. Russian (Национальные рекомендации по антитромботической терапии у больных со стабильными проявлениями атеротромбоза. кардиоваскулярная терапия и профилактика 2009; 8(6), Приложение 6).
4. ESC/EACTS guidelines on myocardial revascularization. European heart Journal 2014 doi:10.1093/eurheartj/ehu278.
5. ACCF/AHA guideline for the Management of st-Elevation Myocardial Infarction. JACC 2013; 61, 4: e78-140.
6. AHA/ACC guideline for the Management of Patients With non–st-Elevation Acute Coronary syndromes. Journal of the American College of Cardiology 2014; 64, 24: e139-e228.
7. EsC guidelines for the management of acute myocardial infarction in patients presenting with st-segment elevation. European heart Journal (2012) 33, 2569-619, doi:10.1093/ eurheartj/ehs215.
8. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation European heart Journal (2011) 32, 2999-3054 doi:10.1093/eurheartj/ehr236.
9. Collaborative meta analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic trialists’ Collaboration. BMJ 2002; 324: 71-86.
10. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Antithrombotic trialists’ (Att) Collaboration. Lancet. 2009 May 30; 373(9678): 1849-60.
11. Mehta SR, tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURREnt-OAsIs 7): a randomised factorial trial. Lancet. 2010 Oct 9;376(9748):1233-43. doi: 10.1016/s0140-6736(10)61088-4.
12. Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (AdAPt-dEs): a prospective multicentre registry study. Lancet 2013; 382: 614-23.
13. Pettersen AA, Seljeflot I, Abdelnoor M, et al. High On-Aspirin Platelet Reactivity and Clinical Outcome in Patients With stable Coronary Artery disease: Results From AsCEt (Aspirin nonresponsiveness and Clopidogrel Endpoint trial). J Am heart Assoc 2012; 1: e000703.
14. Collet JP, Cuisset t, Rangé g, et al. Bedside Monitoring to Adjust Antiplatelet therapy for Coronary stenting. n Engl J Med. 2012 nov 29; 367(22): 2100-9. doi: 10.1056/ nEJMoa1209979.
15. Aradi D, Storey RF, Komocsi A, et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. European heart Journal (2014) 35, 209-215 doi:10.1093/eurheartj/eht375.
16. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. supplementary material. http://eurheartj. oxfordjournals.org/content/ehj/suppl/2013/08/23/eht375.dC1/eht375supp.pdf.
17. Antiplatelet drugs. Antithrombotic therapy and Prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice guidelines. ChEst 2012; 141(2)(suppl): e89s-e119s.
18. Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation. 2005 May 24; 111(20): 2560-4.
19. Gurbel PA, Bliden KP, hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003 Jun 17; 107(23): 2908-13.
20. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004 Jun 29; 109(25): 3171-5.
21. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol. 2006 nov 7; 48(9):1742-50.
22. Buonamici P, Marcucci R, Migliorini A,g. et al. Impact of Platelet Reactivity After Clopidogrel Administration on drug-Eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-7.
23. Snoep JD, Hovens MM, Eikenboom JC, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am heart J. 2007 Aug; 154(2): 221-31.
24. Komarov AL, Shakhmatova OO, Ilushenko TA, et al. Assessment of risk of cardiovascular events in patients of stable coronary artery disease receiving clopidogrel: platelet function or genetic studies? doctor.Ru 2012; 6: 12-20. Russian (А. Л. Комаров, О. О. Шахматова, Т. А. Илющенко, и др. Оценка риска сердечно-сосудистых осложнений у больных стабильной ИБС, получающих клопидогрел: функция тромбоцитов или генетические исследования? доктор.Ру. 2012; 6: 12-20).
25. Tantry US, Bonello L, Aradi D, for the Working group on On-treatment Platelet Reactivity. Consensus and Update on the definition of On-treatment Platelet Reactivity to Adenosine diphosphate Associated With Ischemia and Bleeding. J Am Coll Cardiol 2013; 62: 2261-73.
26. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur heart J 2008;29:992-1000.
27. Price MJ, Berger PB, teirstein Ps, et al. standard- vs high-dose clopidogrel based on platelet function testing after percutaneouscoronary intervention: the gRAVItAs randomized trial. JAMA. 2011 Mar 16;305(11):1097-105. doi: 10.1001/jama.2011.290.
28. Price MJ, Angiolillo dJ, teirstein Ps, et al. Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention. A time-dependent Analysis of the gauging Responsiveness With a Verifynow P2y12 Assay: Impact on thrombosis and safety (gRAVItAs) trial. Circulation. 2011; 124: 1132-7.
29. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020839s048lbl.pdf
30. Mega JL, hochholzer W, Frelinger AL et al. dosing clopidogrel based on CyP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011; 306(20): 2221-8.
31. Collet JP, Cuisset t, Rangé g, et al., for the ARCtIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. n Engl J Med 2012; 367: 2100-9.
32. Trenk d, stone gW, gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the tRIggER-PCI (testing Platelet Reactivity in Patients Undergoing Elective stent Placement on Clopidogrel to guide Alternative therapy With Prasugrel) study. J Am Coll Cardiol 2012; 59: 2159-64.
33. Aradi d, Komocsi A, Price MJ, et al. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis. Int J Cardiol. 2013 sep 1;167(5):2140-8. doi: 10.1016/j.ijcard.2012.05.100.
34. Gibson CM, Chakrabarti AK, Mega J, et al. Reduction of stent thrombosis in Patients With Acute Coronary syndromes treated With Rivaroxaban in AtLAs-ACs 2 tIMI 51 J Am Coll Cardiol 2013; 62: 286-90.
35. Aradi d, tornyos A, Pintér t, et al. Optimizing P2y12 Receptor Inhibition in Patients With Acute Coronary syndrome on the Basis of Platelet Function testing Impact of Prasugrel and high-dose Clopidogrel. J Am Coll Cardiol 2014; 63: 1061-70.
36. Wiviott SD, Braunwald E, McCabe Ch, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. n Engl J Med. 2007 nov 15; 357(20): 2001-15.
37. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. n Engl J Med. 2009 sep 10; 361(11): 1045-57.
38. Price MJ, Murray SS, Angiolillo DJ, et al. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the gIFt (genotype Information and Functional testing) study. J Am Coll Cardiol. 2012 May 29; 59(22): 1928-37.
39. Guskova EV, Panchenko EP, Komarov AL, et al. Residual platelet reactivity to AdP and the risk of bleeding in stable Chd patients receiving double antiplatelet therapy for planned percutaneous coronary intervention. Russ J Cardiol 2015; 3 (119): 35-42. Russian (Е. В. Гуськова, Е. П. Панченко, А. Л. Комаров, и др. Остаточная реактивность тромбоцитов к Адф и риск кровотечений у больных стабильной ибс, получающих двойную антитромбоцитарную терапию в связи с плановым чрескожным коронарным вмешательством. Российский кардиологический журнал 2015; 3 (119): 35-42).
40. Mega JL, Close sL, Wiviott sd, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. n Engl J Med. 2009 Jan 22; 360(4): 354-62.
41. Trenk d, hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681g>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008 May 20; 51(20): 1925-34.
42. Giusti B, Gori AM, Marcucci R, et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol. 2009 Mar 15; 103(6): 806-11.
43. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur heart J. 2009 Apr; 30(8): 916-22.
44. Collet JP, hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009 Jan 24; 373(9660): 309-17.
45. Simon t, Verstuyft C, Mary-Krause M, et al. French Registry of Acute st-Elevation and non-st-Elevation Myocardial Infarction (FAst-MI) Investigators. genetic determinants of response to clopidogrel and cardiovascular events. n Engl J Med. 2009 Jan 22; 360(4): 363-75.
46. Mega JL, Simon t, Anderson JL, et al. CyP2C19 genetic variants and clinical outcomes with clopidogrel: a collaborative meta-analysis. Circulation 2009; 120, 18. suppl.: 598-9. Abstract 2126
47. Mega JL, Simon t, Collet JP, et al. Reduced-function CyP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010; 304, 16: 1821-30.
48. Sibbing d, Koch W, gebhard d, et al. Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and stent thrombosis in Clopidogrel-treated Patients With Coronary stent Placement. Circulation 201;121(4):512-8. doi: 10.1161/ CIRCULAtIOnAhA.109.885194.
49. Komarov AL, Panchenko EP, Donnikov AE, et al. Factors determining the clinical efficacy of clopidogrel and prognosis in patients with stable ischemic heart disease. Cardiology, 2011; 2: 8-18. Russian (комаров А.Л., Панченко Е.П., Донников А.Е. и др. факторы, определяющие клиническую эффективность клопидогрела и прогноз у больных стабильной формой ишемической болезни сердца. кардиология, 2011; 2: 8-18).
50. Xie, et al. Annu Rev Pharmacol toxicol 2001; 41: 815-50.
51. ACCF/AhA Clopidogrel Clinical Alert: Approaches to the FdA “Boxed Warning” A Report of the American College of Cardiology Foundation task Force on Clinical Expert Consensus documents and the American heart Association. JACC 2010; 56, 4, ACCF/AhA Clopidogrel Clinical Alert July 20, 2010: 321-41.
52. The role of testing the functional activity of platelets in the prevention of cardiovascular complications in patients receiving antiplatelet therapy. Conclusion the interdisciplinary Council of Experts of the Russian society of angiologists and vascular surgeons, the Russian scientific society of interventional cardiology, national Association for the fight against stroke, national scientific society of inflammation. Rational pharmacotherapy in cardiology 2014;10(6): 679-87. Russian (Роль тестирования функциональной активности тромбоцитов в профилактике сердечно-сосудистых осложнений у больных, получающих антитромбоцитарную терапию. Заключение междисциплинарного совета экспертов Российского общества ангиологов и сосудистых хирургов, Российского научного общества специалистов по рентгенэндоваскулярной диагностике и лечению, Национальной ассоциации по борьбе с инсультами, Национального научного общества воспаления. Рациональная фармакотерапия в кардиологии 2014;10(6): 679-87).
53. Mahla E, Suarez tA, Bliden KP, et al. Platelet function measurementbased strategy to reduce bleeding and waiting time in clopidogreltreated patients undergoing coronary artery bypass graft surgery: the timing Based on Platelet Function strategy to Reduce Clopidogrel-Associated Bleeding Related to CABg (tARgEt-CABg) study. Circ Cardiovasc Interv 2012; 5: 261-9.
54. Ferraris VA, Saha SP, Oestreich Jh, et al. 2012 update to the society of thoracic surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations. Ann thorac surg 2012; 94: 1761-81.
Рецензия
Для цитирования:
Комаров А.Л., Панченко Е.П. ТЕСТИРОВАНИЕ ФУНКЦИИ ТРОМБОЦИТОВ ДЛЯ ОЦЕНКИ РИСКА ТРОМБОЗОВ И КРОВОТЕЧЕНИЙ У БОЛЬНЫХ ИБС, ПОЛУЧАЮЩИХ АНТИАГРЕГАНТЫ . Российский кардиологический журнал. 2015;(3):25-34. https://doi.org/10.15829/1560-4071-2015-3-25-34
For citation:
Komarov A.L., Panchenko E.P. PLATELET FUNCTION TEST FOR THE ASSESSMENT OF THROMBOSIS AND BLEEDING RISK IN CHD PATIENTS TAKING ANTIPLATELET MEDICATIONS . Russian Journal of Cardiology. 2015;(3):25-34. (In Russ.) https://doi.org/10.15829/1560-4071-2015-3-25-34
Просмотров:
782
Послать статью по эл. почте 